Organization
Hoag Memorial Hospital Presbyterian
2 clinical trials
1 abstract
Abstract
An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT‑112 in human leukocyte antigen-C*08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation.Org: Hoag Memorial Hospital Presbyterian, Newport Beach, CA, Texas Oncology–Baylor Charles A. Sammons Cancer Center, Dallas, TX, Providence Cancer Institute EACRI,
Clinical trial
Somatostatin Receptor Imaging Study of Estrogen Receptor Positive (ER+) Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma: Phase 2 Trial of Clinical ApplicationsStatus: Recruiting, Estimated PCD: 2026-01-31